Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Core Insights - Eledon Pharmaceuticals has enrolled the 80th participant in its Phase 2 BESTOW trial for tegoprubart aimed at preventing kidney transplant rejection [1][2] - The trial has successfully enrolled two-thirds of the projected 120 participants across the United States, Europe, and Latin America, with completion expected by the end of the year [2] - The primary objective of the BESTOW trial is to evaluate graft function at 12 months post-transplant, comparing tegoprubart to tacrolimus, with better graft function linked to improved long-term survival [2][3] Company Overview - Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [4] - The lead investigational product, tegoprubart, is an anti-CD40L antibody targeting CD40 Ligand, which has significant therapeutic potential in various conditions including kidney transplantation and amyotrophic lateral sclerosis (ALS) [4] - The company is headquartered in Irvine, California, and is conducting multiple clinical trials to assess the safety and efficacy of tegoprubart [3][4]